

Form PTO-1449 Modified		DOIPES NOV 11 2001 PATENT & TRADEMARK OFFICE	Docket No. UPN-3832 (L-2091)	Serial No. 09/627,775
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Mark L. Greene, et al.	
U.S. Department of Commerce Patent and Trademark Office			Filing Date July 28, 2000	Group 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
Ac	AA	Bucay, N., et al., "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification," <i>Genes Dev.</i> , May 1, 1998, 12(9), 1260-1268		
	AB	Kong, Y., et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> , January 28, 1999, 397, 315-323		
	AC	Lacey, D.L., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," <i>Cell</i> , April 17, 1998, 93(2), 165-176		
	AD	McOsker, J.E., et al., "Preclinical pharmacology of risedronate, a third generation bisphosphonate," <i>J. Bone & Mineral Research</i> , ISSN: 0884-0431, August 28-31, 1990, page S105, No. 128, Abstract		
	AE	Mortensen, L., et al., "Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up," <i>J. Clinical Endocrinology and Metabolism</i> , February 1998, 83(2), 396-402		
	AF	Shalhoub, V., et al., "Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors," <i>J. Cellular Biochem.</i> , February 1, 1999, 72(2), 251-261		
	AG	Sietsema, W.K., et al., "Antiresorptive dose-responserelationships across three generations of bisphosphonates," <i>Drugs Exptl. Clin. Res.</i> , 1989, XV(9), 389-396		
	AH	Simonet, W.S., et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," <i>Cell</i> , April 18, 1997, 89(2), 309-319		
	AI	Singer, F.R., et al., "Risedronate, a highly effective oral agent in the treatment of patients with severe paget's disease," <i>J. Clinical Endocrinology and Metabolism</i> , June 1998, 83(6), 1906-1910		
KAC	AJ	Siris, E.S., et al., "Risedronate in the treatment of paget's disease of bone: an open label, multicenter study," <i>J. Bone and Mineral Research</i> , June 6, 1998, 13(6), 1032-1038		
EXAMINER		<i>Annu kr. Chakrabarti</i>		DATE CONSIDERED <i>1/10/02</i>

Form PTO-1449 Modified		Docket No. UPN-3832 (L-2091)	Serial No. 09/627,775
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mark L. Greene, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 28, 2000	Group 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AC	AK	Van Beek, E., "Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group," <i>J. Bone and Mineral Research</i> , 1996, 11(10), 1492-1497	
	AL	Frattini, A. et al., "Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis", <i>Nature Genetics</i> , 1999, 23, 447-451	
	AM	Kornak, U. et al., "Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man", <i>Cell</i> , 2001, 104, 205-215	
	AN	Lacey, D.L. et al., "Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo", <i>Am. J. Of Pathology</i> , 2000, 157(2), 435-448	
	AO	Li, Y.P. et al., "Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification", <i>Nature Genetics</i> , 1999, 23, 447-451	
	AP	Li, J. et al., "RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism", <i>PNAS</i> , 2000, 97(4), 1566-1571	
	AQ	Scimeca, J.C., "The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants", <i>Bone</i> , 2000, 26(3), 207-213	
	AR	Shalhoub, V. et al., "Characterization of osteoclast precursors in human blood", <i>British J. Of Haematology</i> , 2000, 111, 501-512	
✓	AS	Weitzmann, M.N. et al., "T cell activation induces human osteoclast formation via receptor activator of nuclear factor k B ligand-dependent and -Independent mechanisms", <i>J. of Bone and Mineral Research</i> , 2001, 16(2), 328-337	
AC			
EXAMINER <i>Arun kr. Chakraborti</i>		DATE CONSIDERED <i>1/10/02</i>	